BACKGROUND

Juvenile onset Recurrent Respiratory Papillomatosis (JoRRP) is a condition in which benign papillomata develop and recur in the larynx. JoRRP usually develops in infancy or early childhood (median age=4 years).\(^1\) It is the most common benign neoplasm of the larynx in children and the second most frequent cause of childhood hoarseness.\(^2\) Common presenting symptoms include: stridor, chronic cough, recurrent pneumonia, failure to thrive, dyspnoea, dysphagia and acute respiratory distress in children with upper respiratory tract infection.\(^3\) Asthma, croup and bronchitis need to be excluded before RRP is diagnosed. In about one third of children with JoRRP the disease spreads into the trachea and bronchi, with the risk of respiratory obstruction.\(^3\) Malignancy is a rare development in RRP.

JoRRP is caused by human papillomavirus (HPV) infection. HPV 6 and HPV 11 are considered the most common causative genotypes.\(^4\) Perinatal transmission from mothers with genital condylomata is thought to be the main method of transmission. Recent evidence also suggests ascending infection through premature rupture of membranes at birth or through handling a neonate by an infected person. A meta-analysis of prospective studies found that mothers whose cervical swabs were HPV-positive on PCR were 5 times more likely to give birth to an HPV-positive infant than were HPV-negative mothers, and that vaginal delivery was twice as likely to result in HPV transmission as was caesarean section.\(^5\) However, the mechanisms of infection have not been fully documented and JoRRP is rare in neonates born to HPV-positive mothers\(^6\), and neonates born vaginally to HPV-negative mothers may be HPV-positive.\(^5,7\)

Treatment is primarily by surgical debulking of papillomata to reduce airway obstruction. Multiple surgeries are common: on average, 4 surgical procedures in the first year after diagnosis.\(^8\) Debulking is usually performed by CO\(_2\) laser, cold steel excision, micro-debrider or, more recently, by office-based laser surgery. Adjuvant treatment using interferon and antivirals (cidofovir, ribavirin) is sometimes used.

The recent introduction of HPV vaccination in Australia has raised the possibility of prevention of RRP. The two HPV vaccines, Cervarix® and Gardasil®, confer protection against HPV 16 and 18 which are responsible for about 70% of cervical cancer worldwide.\(^9\) Gardasil® also offers protection against HPV 6 and 11, which cause genital condylomata and JoRRP. Gardasil® is provided to girls aged 12-13 years, under the National Immunisation Program.\(^10\)

The proposed APSU study will be the first prospective study of RRP worldwide. It will provide an estimate of incidence and data on mode of delivery, maternal history and HPV vaccination status, lesion HPV types, ethnicity, age of onset of diagnosis and duration and nature of treatment. These data are likely to support further research into the biological, maternal and obstetric aspects of RRP. Cases in which HPV typing has been conducted can provide data on the virological characteristics of the disease, from which the impact of HPV vaccination on RRP can be followed.

STUDY OBJECTIVES

1. To estimate the Australian incidence of RRP in children aged <15 years
2. To describe:
   a. Symptoms, clinical presentation and treatment of RRP in Australia.
   b. Characteristics of maternal and delivery history
   c. Child and maternal HPV vaccination history
   d. Viral types isolated in biopsy samples
   e. The distribution of RRP and HPV genotypes according to antenatal maternal HPV vaccination status, and child vaccination status,
   f. Current methods of treatment of JoRRP in Australia

CASE DEFINITION

Please report any infant or child under the age of 15 years diagnosed with Juvenile onset Recurrent Respiratory Papillomatosis (JoRRP) confirmed by endoscopy of the larynx AND by histology.

FOLLOW-UP OF REPORTED CASES

A 2-page questionnaire requesting further details will be forwarded to clinicians who report a case of Juvenile onset Recurrent Respiratory Papillomatosis (JoRRP).

Document Version - 1.3 Document Date – 29 August 2011
INVESTIGATOR CONTACT DETAILS (*Principal Investigator and contact person)

*Dr Daniel Novakovic, Laryngologist ENT, Head and Neck Surgeon, Suite 1, Level 1, 66 Pacific Highway St Leonards NSW 2065 – dnovakov@gmail.com, Phone: 0418-500-067

Dr Alan Cheng, ENT Surgeon, The Children’s Hospital at Westmead, Westmead NSW 2145

Dr Julia Brotherton, Medical Director, National HPV Vaccination Program Register Epidemiologist, Victorian Cytology Service Registries, Level 1, 250 Victoria Parade, East Melbourne VIC 3002

A/Prof Yvonne Zurynski, Deputy Director, Australian Paediatric Surveillance Unit, The Children’s Hospital at Westmead, Westmead NSW 2145

Professor Robert Booy, Head, Clinical Research, National Centre for Immunisation Research and Surveillance, The Children’s Hospital at Westmead, Westmead NSW 2145

Professor Elizabeth Elliott, Director, Australian Paediatric Surveillance Unit, The Children’s Hospital at Westmead, Westmead NSW 2145

A/Prof Paul Walker, John Hunter Hospital, Newcastle, NSW - walkerp@tpg.com.au

A/ Prof Robert Berkowitz, Royal Children’s Hospital, Melbourne, Vic - Robert.Berkowitz@rch.org.au

Dr Henley Harrison, Prince of Wales Children’s Hospital, Randwick NSW - henleyh@bigpond.com

A/Prof Robert Black, Mater Children’s Hospital, Brisbane, Qld - Rob.Black@surgeons.org

A/Prof Chris Perry, Royal Children’s Hospital, Herston, Qld - candkperry@optusnet.com.au

A/Professor Shyan Vijayasekaran, Princess Margaret Hospital for Children, Perth, WA – shyanv@optusnet.com.au

Dr David Wabnitz, Women’s and Children Hospital, Adelaide, SA – damwab@hotmail.com

References


